Page 60 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Precision medicine and beyond in oncology

myeloma patients. BMC Cancer. 2023;23(1):345. monoclonal antibody): A new era in tumor immunotherapy.
Int Immunopharmacol. 2022;113:109365.
doi: 10.1186/s12885-023-10824-3
doi: 10.1016/j.intimp.2022.109365
62. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular
carcinoma. Nat Rev Dis Primers. 2021;7(1):6. 73. Xu RH, Luo H, Lu J, et al. ESCORT-1 : A randomized,
st
double-blind, placebo-controlled, phase 3 trial of
doi: 10.1038/s41572-020-00240-3
camrelizumab plus chemotherapy versus chemotherapy in
63. Housini M, Dariya B, Ahmed N, et al. Colorectal cancer: patients with untreated advanced or metastatic esophageal
Genetic alterations, novel biomarkers, current therapeutic squamous cell carcinoma (ESCC). J Clin Oncol. 2021;39(15
strategies and clinical trials. Gene. 2024;892:147857. suppl):4000.
doi: 10.1016/j.gene.2023.147857 doi: 10.1200/JCO.2021.39.15_suppl.4000
64. Li B, Zhang Q, Castaneda C, Cook S. Targeted therapies 74. Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib
in pancreatic cancer: A new era of precision medicine. versus sorafenib as first-line therapy for unresectable
Biomedicines. 2024;12(10):2175. hepatocellular carcinoma (CARES-310): A randomised,
open-label, international phase 3 study. Lancet.
doi: 10.3390/biomedicines12102175
2023;402(10408):1133-1146.
65. Hong DS, Fakih MG, Strickler JH, et al. KRAS G12C inhibition
with sotorasib in advanced solid tumors. N Engl J Med. doi: 10.1016/s0140-6736(23)00961-3
2020;383(13):1207-1217. 75. Wu X, Sun Y, Yang H, et al. Cadonilimab plus platinum-
based chemotherapy with or without bevacizumab as
doi: 10.1056/NEJMoa1917239
first-line treatment for persistent, recurrent, or metastatic
66. Ou SI, Jänne PA, Leal TA, et al. First-in-human phase I/IB cervical cancer (COMPASSION-16): A randomised,
dose-finding study of adagrasib (MRTX849) in patients with double-blind, placebo-controlled phase 3 trial in China.
advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Lancet. 2024;404(10463):1668-1676.
Oncol. 2022;40(23):2530-2538.
doi: 10.1016/S0140-6736(24)02135-4
doi: 10.1200/jco.21.02752
76. Vergote I, Van Nieuwenhuysen E, O’Cearbhaill RE, %.
67. Chen N, Pu C, Zhao L, et al. Chimeric antigen receptor Tisotumab vedotin in combination with carboplatin,
T cells targeting CD19 and GCC in metastatic colorectal pembrolizumab, or bevacizumab in recurrent or metastatic
cancer: A nonrandomized clinical trial. JAMA Oncol. cervical cancer: Results from the innovaTV 205/GOG-3024/
2024;10(11):1532-1536. ENGOT-cx8 study. J Clin Oncol. 2023;41(36):5536-5549.
doi: 10.1001/jamaoncol.2024.3891 doi: 10.1200/jco.23.00720
68. Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab 77. Oaknin A, Gladieff L, Martínez-García J, et al.
in patients with metastatic colorectal cancer: A phase Ib/II Atezolizumab plus bevacizumab and chemotherapy
clinical trial and gut microbiome analysis. Cell Rep Med. for metastatic, persistent, or recurrent cervical cancer
2021;2(9):100383. (BEATcc): A randomised, open-label, phase 3 trial. Lancet.
2024;403(10421):31-43.
doi: 10.1016/j.xcrm.2021.100383
69. Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo doi: 10.1016/S0140-6736(23)02405-4
plus chemotherapy as first-line treatment in advanced 78. Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A promising
nasopharyngeal carcinoma: A multicenter randomized anti-tumor PD-1 antibody. Mini review. Front Oncol.
phase 3 trial. Nat Med. 2021;27(9):1536-1543. 2020;10:594558.
doi: 10.1038/s41591-021-01444-0 doi: 10.3389/fonc.2020.594558
70. Strickler JH, Rushing CN, Uronis HE, et al. Cabozantinib 79. Al-Salama ZT. Durvalumab: A review in extensive-stage
and panitumumab for RAS wild-type metastatic colorectal SCLC. Targeted Oncol. 2021;16(6):857-864.
cancer. Oncologist. 2021;26(6):e465-e917.
doi: 10.1007/s11523-021-00843-0
doi: 10.1002/onco.13678
80. Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and
71. Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus pharmacodynamics of tremelimumab plus durvalumab
panitumumab in refractory colorectal cancer with mutated for patients with unresectable hepatocellular carcinoma:
KRAS G12C. N Engl J Med. 2023;389(23):2125-2139. Randomized expansion of a phase I/II study. J Clin Oncol.
2021;39(27):2991-3001.
doi: 10.1056/NEJMoa2308795
doi: 10.1200/jco.20.03555
72. Abedi Kiasari B, Abbasi A, Ghasemi Darestani N,
et al. Combination therapy with nivolumab (anti-PD-1 81. Taïeb J, Sayah L, Heinrich K, et al. Efficacy of immune

Volume 8 Issue 3 (2025) 54 doi: 10.36922/ITPS025140018